Zura Bio’s (ZURA) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Zura Bio (NASDAQ:ZURA) in a research note published on Tuesday,Weiss Ratings reports.

Several other equities research analysts have also recently commented on the company. Chardan Capital restated a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a research note on Tuesday, September 30th. Oppenheimer cut their target price on Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, August 15th. Finally, HC Wainwright cut their target price on Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.60.

Zura Bio Price Performance

NASDAQ:ZURA opened at $3.43 on Tuesday. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $5.07. The stock has a market capitalization of $223.02 million, a PE ratio of -4.90 and a beta of 0.25. The business’s 50-day simple moving average is $2.51 and its 200-day simple moving average is $1.70.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. On average, research analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Savant Capital LLC increased its position in shares of Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after purchasing an additional 21,249 shares during the last quarter. Bank of America Corp DE increased its position in shares of Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Zura Bio during the 1st quarter worth approximately $72,000. Nuveen LLC acquired a new position in shares of Zura Bio during the 1st quarter worth approximately $76,000. Finally, Jane Street Group LLC acquired a new position in shares of Zura Bio during the 2nd quarter worth approximately $113,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.